TY - CHAP M1 - Book, Section TI - Risk Assessment and Clinical Management – Pediatric and Other Cancers A1 - Llor, Xavier A1 - Hofstatter, Erin Wysong PY - 2022 T2 - Cancer Genetics: A Clinical Approach AB - Great strides have been made to improve outcomes for pediatric patients suffering from cancer, decreasing mortality by over 50% in the last half century. Despite these advancements in care, cancer remains a leading cause of mortality for children across the world. In the United States alone, approximately 15,800 children under age 20 are diagnosed with cancer annually, and nearly 2,000 are expected to die from the disease. Leukemia, lymphoma, and central nervous system tumors are the most common new cancer diagnoses in the pediatric age group. While many patients and families search for an explanation of why they have been afflicted by such a devastating illness, most pediatric cancers occur without known cause. Until recent years, a very small percentage of pediatric cancer was felt to be related to a genetic predisposition. With the advancement of modern techniques in molecular analysis, more cancer predisposition syndromes have been identified, and an estimated 10% of pediatric patients with cancer have a heritable cause. Early identification of these patients and initiation of cancer surveillance protocols is essential for reducing cancer-related mortality.1–4 SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1182367115 ER -